1 Min Read
* CURIS ANNOUNCES INITIATION OF PHASE 1 TRIAL OF CA-4948, A SMALL MOLECULE INHIBITOR OF IRAK4 KINASE IN PATIENTS WITH LYMPHOMA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.